NO951307L - Terapeutiske anti-HIV oligonukleotider - Google Patents

Terapeutiske anti-HIV oligonukleotider

Info

Publication number
NO951307L
NO951307L NO951307A NO951307A NO951307L NO 951307 L NO951307 L NO 951307L NO 951307 A NO951307 A NO 951307A NO 951307 A NO951307 A NO 951307A NO 951307 L NO951307 L NO 951307L
Authority
NO
Norway
Prior art keywords
oligonucleotides
hiv
therapeutic anti
disclosed
nucleotides
Prior art date
Application number
NO951307A
Other languages
English (en)
Other versions
NO951307D0 (no
Inventor
Sudhir Agrawal
Jin Yan Tang
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Publication of NO951307D0 publication Critical patent/NO951307D0/no
Publication of NO951307L publication Critical patent/NO951307L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oligonukleotider med nukleotidsekvenser som hybridi- serer til minst nukleotldene 324 til 348 av en konservert gag region til HIV-1 genomet er beskrevet. Disse ollgonukleotldene har omtrent 25 til 30 nukleo- tider koblet med minst en ikke-fosfodlester inter- nukleotidblndlng som gjør dem motstandsdyktige for nuklease spaltning. Også beskrevet er terapeutiske formuleringer inneholdende silke oligonukleotider og fremgangsmåter for inhibering av HIV-1 proliferasjon og behandling av HIV-1 infeksjon i et pattedyr.
NO951307A 1992-10-05 1995-04-04 Terapeutiske anti-HIV oligonukleotider NO951307L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95813592A 1992-10-05 1992-10-05
PCT/US1993/009392 WO1994008004A1 (en) 1992-10-05 1993-10-04 Therapeutic anti-hiv oligonucleotide and pharmaceutical

Publications (2)

Publication Number Publication Date
NO951307D0 NO951307D0 (no) 1995-04-04
NO951307L true NO951307L (no) 1995-06-01

Family

ID=25500631

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951307A NO951307L (no) 1992-10-05 1995-04-04 Terapeutiske anti-HIV oligonukleotider

Country Status (19)

Country Link
US (1) US5684147A (no)
EP (1) EP0664833B1 (no)
JP (1) JPH08504570A (no)
KR (1) KR950704482A (no)
AT (1) ATE146819T1 (no)
AU (1) AU678415B2 (no)
BR (1) BR9307191A (no)
CA (1) CA2146364A1 (no)
CZ (1) CZ85495A3 (no)
DE (1) DE69306969T2 (no)
DK (1) DK0664833T3 (no)
ES (1) ES2096343T3 (no)
FI (1) FI951600A (no)
GR (1) GR3022315T3 (no)
HU (1) HUT72400A (no)
NO (1) NO951307L (no)
NZ (1) NZ257434A (no)
PL (1) PL308261A1 (no)
WO (1) WO1994008004A1 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US5733781A (en) * 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
EP1584681A3 (en) * 1997-07-10 2005-11-09 GeneSense Technologies Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
ES2255732T3 (es) 1997-08-19 2006-07-01 Idera Pharmaceuticals, Inc. Oligonucleotidos especificos de vih y procedimientos para su utilizacion.
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
JP4854853B2 (ja) 1998-11-12 2012-01-18 ライフ テクノロジーズ コーポレーション トランスフェクション薬剤
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
ATE456677T1 (de) 1999-07-09 2010-02-15 Gen Probe Inc Hiv-1 detektion mittels nukleinsäureamplifizierung
AU780116B2 (en) * 1999-12-23 2005-03-03 Board Of Regents, The University Of Texas System Inhibition of cellular proteases
EP1322655B1 (en) * 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP2002125687A (ja) * 2000-10-30 2002-05-08 Tosoh Corp Ｈｉｖ−１検出のためのオリゴヌクレオチドおよび検出法
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US8834900B2 (en) 2001-08-17 2014-09-16 University Of Iowa Research Foundation Combination motif immune stimulatory oligonucleotides with improved activity
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1647595A1 (en) * 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
US8399423B2 (en) * 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2007058527A2 (en) 2005-11-17 2007-05-24 Academisch Medisch Centrum Inducible expression systems
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
CA2633157C (en) 2005-12-09 2018-10-09 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
EP2454283B1 (en) 2009-07-15 2018-03-14 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2012072814A1 (en) 2010-12-02 2012-06-07 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
EP2691530B1 (en) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2015027334A1 (en) * 2013-08-26 2015-03-05 The Royal Institution For The Advancement Of Learning / Mcgill University Antisense-based small rna agents targeting the gag open reading frame of hiv-1 rna
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE208813T1 (de) * 1988-02-16 2001-11-15 Greatbatch Gen Aid Ltd Modifizierte zellen mit resistenz gegen retroviralinfektionen
JPH04501052A (ja) * 1988-02-26 1992-02-27 ザ・ウスター・フアウンデーシヨン・フオー・バイオメデイカル・リサーチ 外来性オリゴヌクレオチドによるｈｔｌｖ―３の抑制

Also Published As

Publication number Publication date
PL308261A1 (en) 1995-07-24
EP0664833B1 (en) 1996-12-27
FI951600A (fi) 1995-05-10
WO1994008004A1 (en) 1994-04-14
FI951600A0 (fi) 1995-04-04
JPH08504570A (ja) 1996-05-21
NZ257434A (en) 1997-01-29
DE69306969D1 (de) 1997-02-06
EP0664833A1 (en) 1995-08-02
GR3022315T3 (en) 1997-04-30
CA2146364A1 (en) 1994-04-14
DK0664833T3 (da) 1997-04-14
ES2096343T3 (es) 1997-03-01
BR9307191A (pt) 1999-03-30
ATE146819T1 (de) 1997-01-15
CZ85495A3 (en) 1996-03-13
HUT72400A (en) 1996-04-29
US5684147A (en) 1997-11-04
NO951307D0 (no) 1995-04-04
KR950704482A (ko) 1995-11-20
DE69306969T2 (de) 1997-05-07
AU5402894A (en) 1994-04-26
AU678415B2 (en) 1997-05-29
HU9500995D0 (en) 1995-06-28

Similar Documents

Publication Publication Date Title
NO951307L (no) Terapeutiske anti-HIV oligonukleotider
AU8771398A (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
ATE181960T1 (de) Gegensinnige hemmer des humanen immunmangel virus (hiv)
ATE202383T1 (de) Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten
CA2165821A1 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
WO1994024144A3 (en) Enhanced triple-helix and double-helix formation with oligomers containing modified purines
DK0677056T3 (da) Oligonukleotid-alkylphosphonater og -alkylphosphonothioater
CA2220433A1 (en) Il-6 activity inhibitor
FI946201A0 (fi) Itsestabiloidut oligonukleotidit terapeuttisina aineina
NO971493D0 (no) Virusmateriale og nukleotidfragmenter som er forbundet med multippel sklerose, og som kan anvendes til diagnostiske, preventive og terapeutiske formål
HUP0103465A2 (hu) A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok
KR960704034A (ko) 단백질 생산, 세포 증식 및(또는) 전염병 병원균의 증식에 대한 올리고뉴클레오티드 저해의 향상법(Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and/or Multiplication of Infectious Disease Pathogens)
EP0503002A4 (en) Antisense oligonucleotide inhibition of papillomavirus
AP1674A (en) The genome of the HIV-1 inter-subtype (C/B') and use thereof.
ATE160354T1 (de) Oligonukleotide mit anti-cytomegalovirus wirkung
MX9707674A (es) Uso de una linfosina que suprime el virus de inmunodeficiencia (isl) para inhibir la replicacion de los virus, en particular de los retrovirus.
TH23381A (th) โอลิโกนิวคลีโอไทด์สำหรับยับยั้งการแสดงลักษณะของไอโซพรีนิลโปรตีนทรานสเฟอเรส
TH28996B (th) "โอลิโกนิวคลีโอไทด์จำเพาะสำหรับไวรัสตับอักเสบ c